Vanda Pharmaceuticals (VNDA) Operating Margin (2016 - 2025)
Vanda Pharmaceuticals (VNDA) has disclosed Operating Margin for 16 consecutive years, with 70.53% as the latest value for Q4 2025.
- Quarterly Operating Margin fell 5120.0% to 70.53% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.95% through Dec 2025, down 4950.0% year-over-year, with the annual reading at 69.95% for FY2025, 4950.0% down from the prior year.
- Operating Margin hit 70.53% in Q4 2025 for Vanda Pharmaceuticals, down from 55.61% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 18.22% in Q2 2021 to a low of 81.99% in Q1 2025.
- Historically, Operating Margin has averaged 16.28% across 5 years, with a median of 14.09% in 2023.
- Biggest five-year swings in Operating Margin: skyrocketed 1672bps in 2021 and later tumbled -6253bps in 2025.
- Year by year, Operating Margin stood at 12.7% in 2021, then fell by -19bps to 10.28% in 2022, then tumbled by -252bps to 15.67% in 2023, then dropped by -23bps to 19.33% in 2024, then crashed by -265bps to 70.53% in 2025.
- Business Quant data shows Operating Margin for VNDA at 70.53% in Q4 2025, 55.61% in Q3 2025, and 73.21% in Q2 2025.